{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:23:24Z","timestamp":1781742204521,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services"},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SKG Jebsen Foundation"},{"name":"Helseregion Vest"},{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Constitutional <jats:italic>BRCA1<\/jats:italic> epimutations (promoter hypermethylation) are associated with an elevated risk of triple-negative breast cancer and high-grade serous ovarian cancer. While <jats:italic>MGMT<\/jats:italic> epimutations are frequent in colon cancer, glioblastoma, and B-cell lymphoma, it remains unknown whether constitutional <jats:italic>MGMT<\/jats:italic> epimutations are associated with risk of any of these malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We designed a nested case\u2013control study, assessing potential associations between <jats:italic>MGMT<\/jats:italic> epimutations in blood from healthy individuals and subsequent risk of incident cancer. The study cohort was drawn from postmenopausal women, participating in the Women\u2019s Health Initiative (WHI) study, who had not been diagnosed with either colon cancer, glioblastoma, or B-cell lymphoma prior to study entry. The protocol included <jats:italic>n<\/jats:italic>\u2009=\u2009400 women developing incident left-sided and <jats:italic>n<\/jats:italic>\u2009=\u2009400 women developing right-sided colon cancer, <jats:italic>n<\/jats:italic>\u2009=\u2009400 women developing diffuse large B-cell lymphomas, all matched on a 1:2 basis with cancer-free controls, and <jats:italic>n<\/jats:italic>\u2009=\u2009195 women developing incident glioblastoma multiforme, matched on a 1:4 basis. All cancers were confirmed in centralized medical record review. Blood samples, collected at entry, were analyzed for <jats:italic>MGMT<\/jats:italic> epimutations by massive parallel sequencing. Associations between <jats:italic>MGMT<\/jats:italic> methylation and incident cancers were analyzed by Cox proportional hazards regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Analyzing epimutations affecting the key regulatory area of the <jats:italic>MGMT<\/jats:italic> promoter, the hazard ratio (HR) was 1.07 (95% CI 0.79\u20131.45) and 0.80 (0.59\u20131.08) for right- and left-sided colon cancer, respectively, 1.13 (0.78\u20131.64) for glioblastoma, and 1.11 (0.83\u20131.48) for diffuse large B-cell lymphomas. Sensitivity analyses limited to subregions of the <jats:italic>MGMT<\/jats:italic> promoter and to individuals with different genotypes of a functional SNP in the <jats:italic>MGMT<\/jats:italic> promoter (rs16906252), revealed no significant effect on HR for any of the cancer forms.\u00a0Neither did we observe any effect of rs16906252 status on HR for any of the cancer forms among individuals methylated or non-methylated at the <jats:italic>MGMT<\/jats:italic> promoter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Constitutional <jats:italic>MGMT<\/jats:italic> promoter methylation in normal tissue is not associated with an increased risk of developing colon cancer, glioblastoma, or B-cell lymphoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13148-025-01835-x","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:17:08Z","timestamp":1740028628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas"],"prefix":"10.1186","volume":"17","author":[{"given":"Oleksii","family":"Nikolaienko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnet L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan T.","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per E.","family":"L\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"10","key":"1835_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41580-018-0028-8","volume":"19","author":"V Haberle","year":"2018","unstructured":"Haberle V, Stark A. Eukaryotic core promoters and the functional basis of transcription initiation. Nat Rev Mol Cell Biol. 2018;19(10):621\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"1835_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1043-2760(00)00248-4","volume":"11","author":"J Newell-Price","year":"2000","unstructured":"Newell-Price J, Clark AJL, King P. DNA methylation and silencing of gene expression. Trends Endocrinol Metab. 2000;11(4):142\u20138.","journal-title":"Trends Endocrinol Metab"},{"issue":"24","key":"1835_CR3","first-page":"7213","volume":"62","author":"JA Fahrner","year":"2002","unstructured":"Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Can Res. 2002;62(24):7213\u20138.","journal-title":"Can Res"},{"issue":"3","key":"1835_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ccell.2015.07.012","volume":"28","author":"T Mazor","year":"2015","unstructured":"Mazor T, Pankov A, Johnson BE, Hong CB, Hamilton EG, Bell RJA, et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell. 2015;28(3):307\u201317.","journal-title":"Cancer Cell"},{"issue":"10","key":"1835_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc4001","volume":"15","author":"MP Hitchins","year":"2015","unstructured":"Hitchins MP. Constitutional epimutation as a mechanism for cancer causality and heritability? Nature Rev Cancer. 2015;15(10):181\u201394.","journal-title":"Nature Rev Cancer"},{"key":"1835_CR6","doi-asserted-by":"crossref","unstructured":"Sloane MA, Ward RL, Hesson LB. Defining the criteria for identifying constitutional epimutations. Clin Epigenet. 2016;8.","DOI":"10.1186\/s13148-016-0207-4"},{"issue":"2","key":"1835_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10689-013-9613-3","volume":"12","author":"MP Hitchins","year":"2013","unstructured":"Hitchins MP. The role of epigenetics in Lynch syndrome. Fam Cancer. 2013;12(2):189\u2013205.","journal-title":"Fam Cancer"},{"issue":"3","key":"1835_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.gde.2010.02.005","volume":"20","author":"LB Hesson","year":"2010","unstructured":"Hesson LB, Hitchins MP, Ward RL. Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev. 2010;20(3):290\u20138.","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"1835_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ccr.2011.07.003","volume":"20","author":"MP Hitchins","year":"2011","unstructured":"Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong JJL, Khachigian LM, et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5 \u2019 UTR. Cancer Cell. 2011;20(2):200\u201313.","journal-title":"Cancer Cell"},{"issue":"8","key":"1835_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jmedgenet-2011-100050","volume":"48","author":"M Morak","year":"2011","unstructured":"Morak M, Koehler U, Schackert HK, Steinke V, Royer-Pokora B, Schulmann K, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. J Med Genet. 2011;48(8):513\u20139.","journal-title":"J Med Genet"},{"issue":"10","key":"1835_CR11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/ijc.24230","volume":"124","author":"A Gylling","year":"2009","unstructured":"Gylling A, Ridanpaa M, Vierimaa O, Aittomaki K, Avela K, Kaariainen H, et al. Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer. 2009;124(10):2333\u201340.","journal-title":"Int J Cancer"},{"issue":"2","key":"1835_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajhg.2018.07.002","volume":"103","author":"DGR Evans","year":"2018","unstructured":"Evans DGR, van Veen EM, Byers HJ, Wallace AJ, Ellingford JM, Beaman G, et al. A Dominantly inherited 5\u2019 UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet. 2018;103(2):213\u201320.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1835_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ng.283","volume":"41","author":"MJL Ligtenberg","year":"2009","unstructured":"Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3 \u2019 exons of TACSTD1. Nat Genet. 2009;41(1):112\u20137.","journal-title":"Nat Genet"},{"issue":"4","key":"1835_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.15698\/cst2019.04.183","volume":"3","author":"PE L\u00f8nning","year":"2019","unstructured":"L\u00f8nning PE, Eikesdal HP, Loes IM, Knappskog S. Constitutional mosaic epimutations\u2014A hidden cause of cancer? Cell Stress. 2019;3(4):118\u201335.","journal-title":"Cell Stress"},{"issue":"11","key":"1835_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1001\/jamaoncol.2022.3846","volume":"8","author":"PE L\u00f8nning","year":"2022","unstructured":"L\u00f8nning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, et al. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. JAMA Oncol. 2022;8(11):1579\u201387.","journal-title":"JAMA Oncol"},{"key":"1835_CR16","doi-asserted-by":"crossref","unstructured":"Nikolaienko O, Eikesdal HP, Ognedal E, Gilje B, Lundgren S, Blix ES, et al. Prenatal <i>BRCA1<\/i> epimutations contribute significantly to triple-negative breast cancer development. Genome Med.. 2023;15(1).","DOI":"10.1186\/s13073-023-01262-8"},{"issue":"10","key":"1835_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"10","key":"1835_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/1940-6207.CAPR-09-0056","volume":"2","author":"ILM Candiloro","year":"2009","unstructured":"Candiloro ILM, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res. 2009;2(10):862\u20137.","journal-title":"Cancer Prev Res"},{"key":"1835_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-018-0529-5","volume":"10","author":"N Al-Moghrabi","year":"2018","unstructured":"Al-Moghrabi N, Al-Showimi M, Al-Yousef N, Al-Shahrani B, Karakas B, Alghofaili L, et al. Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters. Clin Epigenet. 2018;10:1\u201310.","journal-title":"Clin Epigenet"},{"issue":"12","key":"1835_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/neuonc\/nov064","volume":"17","author":"RW Rapkins","year":"2015","unstructured":"Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, et al. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 2015;17(12):1589\u201398.","journal-title":"Neuro Oncol"},{"issue":"2","key":"1835_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.lungcan.2010.05.008","volume":"71","author":"LS Kristensen","year":"2011","unstructured":"Kristensen LS, Nielsen HM, Hager H, Hansen LL. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer. 2011;71(2):130\u20136.","journal-title":"Lung Cancer"},{"key":"1835_CR22","doi-asserted-by":"crossref","unstructured":"Kristensen LS, Treppendahl MB, Asmar F, Girkov MS, Nielsen HM, Kjeldsen TE, et al. Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep. 2013;3.","DOI":"10.1038\/srep02789"},{"issue":"7","key":"1835_CR23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1158\/1078-0432.CCR-10-3026","volume":"17","author":"SG Leng","year":"2011","unstructured":"Leng SG, Bernauer AM, Hong CB, Do KC, Yingling CM, Flores KG, et al. The A\/G Allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res. 2011;17(7):2014\u201323.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1835_CR24","first-page":"793","volume":"59","author":"M Esteller","year":"1999","unstructured":"Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793\u20137.","journal-title":"Cancer Res"},{"issue":"22","key":"1835_CR25","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1093\/nar\/22.22.4614","volume":"22","author":"LC Harris","year":"1994","unstructured":"Harris LC, Remack JS, Brent TP. Identification OF A 59-BP enhancer located at the first exon-intron boundary of the human O-6-methylguanine DNA methyltransferase gene. Nucleic Acids Res. 1994;22(22):4614\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"24","key":"1835_CR26","doi-asserted-by":"publisher","first-page":"6266","DOI":"10.1158\/1078-0432.CCR-15-2765","volume":"22","author":"J Kuroiwa-Trzmielina","year":"2016","unstructured":"Kuroiwa-Trzmielina J, Wang F, Rapkins RW, Ward RL, Buchanan DD, Win AK, et al. SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing <i>MGMT<\/i>-methylated colorectal cancer. Clin Cancer Res. 2016;22(24):6266\u201377.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1835_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jnci\/94.1.26","volume":"94","author":"M Esteller","year":"2002","unstructured":"Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, et al. Hypermethylation of the DNA repair gene O-6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94(1):26\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1835_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2353\/jmoldx.2006.050052","volume":"8","author":"T Sugai","year":"2006","unstructured":"Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K, Nakamura S. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis\u2014proposal for new molecular profile of colorectal carcinomas. J Molecul Diagn. 2006;8(2):193\u2013201.","journal-title":"J Molecul Diagn"},{"issue":"4","key":"1835_CR29","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1007\/s11033-019-04856-x","volume":"46","author":"SA Shawky","year":"2019","unstructured":"Shawky SA, El-Borai MH, Khaled HM, Guda I, Mohanad M, Abdellateif MS, et al. The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. Mol Biol Rep. 2019;46(4):4063\u201376.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"1835_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.pas.0000155144.53047.7d","volume":"29","author":"LR Chirieac","year":"2005","unstructured":"Chirieac LR, Shen LL, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29(4):429\u201336.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1835_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","volume":"19","author":"G Anderson","year":"1998","unstructured":"Anderson G, Cummings S, Freedman LS, Furberg C, Henderson M, Johnson SR, et al. Design of the women\u2019s health initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61\u2013109.","journal-title":"Control Clin Trials"},{"issue":"9","key":"1835_CR32","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S1047-2797(03)00043-7","volume":"13","author":"GL Anderson","year":"2003","unstructured":"Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the women\u2019s health initiative study design. Ann Epidemiol. 2003;13(9):S5\u201317.","journal-title":"Ann Epidemiol"},{"key":"1835_CR33","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.1038\/s41598-019-47642-2","volume":"9","author":"A Estival","year":"2019","unstructured":"Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, et al. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Sci Rep. 2019;9:11125.","journal-title":"Sci Rep"},{"issue":"7","key":"1835_CR34","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/ijms24076184","volume":"24","author":"KR Brawanski","year":"2023","unstructured":"Brawanski KR, Sprung S, Freyschlag CF, Hoeftberger R, Strobel T, Haybaeck J, et al. Influence of MMR, MGMT promotor methylation and protein expression on overall and progression-free survival in primary glioblastoma patients treated with temozolomide. Int J Mol Sci. 2023;24(7):6184.","journal-title":"Int J Mol Sci"},{"key":"1835_CR35","first-page":"100667","volume":"42","author":"GL Jensen","year":"2023","unstructured":"Jensen GL, Pourfarrokh N, Volz M, Morales LL, Walker K, Hammonds KP, et al. Improved pathologic response to chemoradiation in MGMT methylated locally advanced rectal cancer. Clin Transl Radiat Oncol. 2023;42:100667.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1835_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/neup.12887","volume":"43","author":"VG Jimenez","year":"2023","unstructured":"Jimenez VG, Doval MB, Bellvert CG, Goliney VG, Asencio OS, Martin AG, Dominguez JI. Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma. Neuropathology. 2023;43:306.","journal-title":"Neuropathology"},{"issue":"9","key":"1835_CR37","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1128\/MCB.17.9.5612","volume":"17","author":"GS Watts","year":"1997","unstructured":"Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O-6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997;17(9):5612\u20139.","journal-title":"Mol Cell Biol"},{"issue":"17","key":"1835_CR38","first-page":"3672","volume":"57","author":"XLC Qian","year":"1997","unstructured":"Qian XLC, Brent TP. Methylation hot spots in the 5\u2019 flanking region denote silencing of the O-6-methylguanine-DNA methyltransferase gene. Can Res. 1997;57(17):3672\u20137.","journal-title":"Can Res"},{"key":"1835_CR39","doi-asserted-by":"publisher","first-page":"giad087","DOI":"10.1093\/gigascience\/giad087","volume":"12","author":"O Nikolaienko","year":"2023","unstructured":"Nikolaienko O, Lonning PE, Knappskog S. epialleleR: an R\/Bioconductor package for sensitive allele-specific methylation analysis in NGS data. Gigascience. 2023;12:giad087.","journal-title":"Gigascience"},{"issue":"22","key":"1835_CR40","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1093\/nar\/19.22.6163","volume":"19","author":"LC Harris","year":"1991","unstructured":"Harris LC, Potter PM, Tano K, Shiota S, Mitra S, Brent TP. Characterization of the promoter region of the human O6-methylguanine-dna methyltransferase gene. Nucleic Acids Res. 1991;19(22):6163\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1835_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-011-0803-5","volume":"121","author":"DS Malley","year":"2011","unstructured":"Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 2011;121(5):651\u201361.","journal-title":"Acta Neuropathol"},{"issue":"22","key":"1835_CR42","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/jnci\/85.22.1819","volume":"85","author":"RG Ziegler","year":"1993","unstructured":"Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AMY, West DW, et al. Migration patterns and breast-cancer risk in Asian-American Women. JNCI J Nat Cancer Instit. 1993;85(22):1819\u201327.","journal-title":"JNCI J Nat Cancer Instit"},{"issue":"2","key":"1835_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00001648-199503000-00017","volume":"6","author":"JL Stanford","year":"1995","unstructured":"Stanford JL, Herrinton LJ, Schwartz SM, Weiss NS. Breast-cancer incidence in Asian migrants to the United-States and their descendants. Epidemiology. 1995;6(2):181\u20133.","journal-title":"Epidemiology"},{"key":"1835_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4444-0","volume":"18","author":"J Shuldiner","year":"2018","unstructured":"Shuldiner J, Liu Y, Lofters A. Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004\u20132014. BMC Cancer. 2018;18:1.","journal-title":"BMC Cancer"},{"issue":"18","key":"1835_CR45","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0959-8049(02)00496-3","volume":"38","author":"K Hemminki","year":"2002","unstructured":"Hemminki K, Li X. Cancer risks in Nordic immigrants and their offspring in Sweden. Eur J Cancer. 2002;38(18):2428\u201334.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1835_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13148-019-0726-x","volume":"11","author":"L Ferrari","year":"2019","unstructured":"Ferrari L, Carugno M, Bollati V. Particulate matter exposure shapes DNA methylation through the lifespan. Clin Epigenet. 2019;11(1):129.","journal-title":"Clin Epigenet"},{"issue":"8","key":"1835_CR47","doi-asserted-by":"publisher","first-page":"10143","DOI":"10.3390\/ijms130810143","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Li SSL. Epigenetic effects of environmental chemicals bisphenol A and phthalates. Int J Mol Sci. 2012;13(8):10143\u201353.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1835_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13148-019-0713-2","volume":"11","author":"CF Rider","year":"2019","unstructured":"Rider CF, Carlsten C. Air pollution and DNA methylation: effects of exposure in humans. Clin Epigenet. 2019;11(1):131.","journal-title":"Clin Epigenet"},{"issue":"1","key":"1835_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/hdy.2010.2","volume":"105","author":"V Bollati","year":"2010","unstructured":"Bollati V, Baccarelli A. Environmental epigenetics. Heredity. 2010;105(1):105\u201312.","journal-title":"Heredity"},{"issue":"30","key":"1835_CR50","doi-asserted-by":"publisher","first-page":"10604","DOI":"10.1073\/pnas.0500398102","volume":"102","author":"MF Fraga","year":"2005","unstructured":"Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestart ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 2005;102(30):10604\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1835_CR51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759\u201367.","journal-title":"Cell"},{"issue":"19","key":"1835_CR52","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1835_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2020.09.058","volume":"160","author":"WM Grady","year":"2021","unstructured":"Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology. 2021;160(3):690\u2013709.","journal-title":"Gastroenterology"},{"issue":"3","key":"1835_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/1078-0432.1203.11.3","volume":"11","author":"Z Petko","year":"2005","unstructured":"Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, et al. Aberrantly methylated <i>CDKN2A<\/i>, <i>MGMT<\/i>, and <i>MLH1<\/i> in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11(3):1203\u20139.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1835_CR55","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/jnci\/dji275","volume":"97","author":"LL Shen","year":"2005","unstructured":"Shen LL, Kondo Y, Rosner GL, Xiao LC, Hernandez NS, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97(18):1330\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1835_CR56","first-page":"429","volume":"16","author":"CZ Ye","year":"2006","unstructured":"Ye CZ, Shrubsole MJ, Cai QY, Ness R, Grady WM, Smalley W, et al. Promoter methylation status of the <i>MGMT<\/i>, <i>hMLH1<\/i>, and <i>CDKN2A\/p16<\/i> genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep. 2006;16(2):429\u201335.","journal-title":"Oncol Rep"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01835-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:04:41Z","timestamp":1747325081000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01835-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01835-x","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Norwegian Region North Ethical Committee; ref no 241802.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr L\u00f8nning has received speaker\u2019s honoraria from Illumina. Dr. Knappskog has received research funding for other projects from AstraZeneca, Pfizer, and Illumina, and speaker\u2019s bureaux honoraria from AstraZeneca, Pfizer, Pierre Fabre, and Novartis. Dr Chlebowski is a consultant for Pfizer and UpToDate. No other author reported conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}